Skip to main content

Table 2 Cycle characteristics and embryological outcomes of women in two groups

From: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial

Characteristics

MPA + HMG Group

(n = 150)

Ultra-long Group

(n = 150)

P

hMG dose (IU)

1882.50 ± 388.77

2456.50 ± 560.17*

 < 0.001

hMG duration, days

8.72 ± 1.48

11.31 ± 2.26*

 < 0.001

hMG dose per follicle, IU

225.25 ± 130.47

282.18 ± 267.05*

0.02

The level of E2 per mature follicle (ng/ml)

272.47 ± 91.68

232.55 ± 92.32*

 < 0.001

FOI

89.83 (1395/1553)

97.02 (1400/1443)

 < 0.001

Cancelled cycle

0

0

/

No. of > 10 mm follicles on the triggering day

10.70 ± 5.27

12.28 ± 6.60*

0.023

No. of > 14 mm follicles on the triggering day

7.09 ± 3.82

8.79 ± 5.11*

0.001

No. of > 10 mm follicles on oocytes pick up day

12.41 ± 5.47

14.21 ± 6.96*

0.013

No. of oocytes punctured

12.68 ± 7.11

13.55 ± 7.49

0.301

Oocytes retrieved (n)

9.30 ± 5.73

9.33 ± 5.36

0.959

MII oocytes (n)

7.77 ± 5.23

8.23 ± 4.93

0.434

Fertilized oocytes (n)

6.73 ± 5.00

6.92 ± 4.35

0.722

Top-quality embryos (n)

2.69 ± 2.43

2.43 ± 2.44

0.368

Viable embryos (n)

3.09 ± 2.46

3.07 ± 2.38

0.943

Oocyte retrieval rate, %

73.34 (1395/1902)

68.86 (1400/2033)

0.38

Mature oocyte rate, %

83.58 (1166/1395)

88.21 (1235/1400)*

 < 0.001

Fertilization rate, %

65.23 (910/1395)

65.35 (915/1400)

0.945

ICSI rate, %

31.33 (47/150)

40.6 7(61/150)

0.092

Fertilization rate for ICSI, %

90.13 (283/314)

84.40 (357/423)*

0.023

Cleavage rate, %

97.03 (883/910)

97.81 (995/915)

0.292

High quality embryo rate, %

28.89 (403/1395)

26.07 (365/1400)

0.095

Viable embryo rate, %

33.26 (464/1395)

32.93 (461/1400)

0.852

Cancellation rate, %

14 (21/150)

8.67 (13/150)

0.380

Premature LH rate, %

0

0

/

Incidence of OHSS, %

0

0

/

  1. *P < 0.05 MPA + HMG group vs. Ultra-long group
  2. MPA, medroxyprogesterone acetate; HMG, human menopausal gonadotropin